The NAM co-cultures were treated with CSF from eight AD patients (four patients belonging to the group Aβ+Tau and four patients to the group Aβ-Tau) and four non-AD patients (group non-AD) while the control wells were treated with the same volume of CSF used by complete sterile PBS. This evidence concerns the gene MAPT and Alzheimer disease.